EyeGene Inc is a pioneering company that values innovation and technological advancements in the field of ocular health. With their unwavering commitment to delivering effective solutions, EyeGene Inc aims to improve the quality of life for individuals affected by eye-related conditions. Their corporate philosophy centers around cutting-edge research, development, and commercialization of groundbreaking therapies. By embracing collaboration with experts, EyeGene Inc strives to create products that exhibit the highest standards of safety, efficacy, and reliability. With a steadfast dedication to addressing unmet needs, EyeGene Inc is poised to revolutionize the industry and provide hope for those seeking improved vision and ocular well-being.

EyeGene Inc is primarily present in the United States, with headquarters located in California. While the company's main focus is on the domestic market, EyeGene Inc has also expanded its presence internationally, with a growing presence in various countries and regions. These include but are not limited to Canada, Europe, Asia, and Australia. With its global footprint, EyeGene Inc aims to provide its innovative products and services to a wide range of customers, ensuring its commitment to international growth and market expansion.

EyeGene Inc has achieved several significant milestones throughout its history. One notable achievement is the successful development and commercialization of innovative gene therapy products for various ocular disorders. The company's dedication to research and development has led to groundbreaking treatments that have positively impacted the lives of patients. EyeGene Inc has also made significant progress in gaining regulatory approvals for its products, expanding its market reach, and fostering strategic partnerships with key stakeholders in the healthcare industry. These milestones highlight EyeGene Inc's commitment to advancing eye care and its commitment to being at the forefront of the industry.

EyeGene Inc is a renowned company specializing in medical technology and genetic research. Founded in [year], EyeGene Inc has emerged as a leading player in the field. The company is dedicated to developing innovative solutions for various eye disorders and diseases. With a strong focus on research and development, EyeGene Inc has made significant contributions to the medical community. Its advanced technology, coupled with a team of experienced professionals, has helped transform the diagnosis and treatment of ocular conditions. EyeGene Inc remains committed to improving the lives of individuals affected by eye-related ailments through cutting-edge solutions and breakthrough discoveries.

The main competitors of EyeGene Inc in the market are companies A, B, and C. These competitors are known for their similar product offerings and have a significant presence in the industry. EyeGene Inc faces tough competition from these companies in terms of market share and product innovation. However, EyeGene Inc differentiates itself through its unique features and strong customer base. Despite the competition, EyeGene Inc continues to strive for excellence and remains a key player in the market.

EyeGene Inc is primarily active in the biotechnology and healthcare industries.

The business model of EyeGene Inc is focused on developing and commercializing innovative gene therapies for various ocular diseases. EyeGene Inc aims to utilize cutting-edge genetic technologies to target and modify specific genes involved in eye-related disorders. By doing so, the company strives to offer potential solutions for conditions such as genetic retinal diseases and glaucoma. With its expertise in gene therapy, EyeGene Inc aims to pave the way for advanced treatments to address unmet medical needs in the field of ophthalmology.

EyeGene P/E suhe on −0,07.

EyeGene KUV on 16,54.

AlleAktien kvaliteediskoor ettevõttele EyeGene on 6/10.

oodatud EyeGene käive on 4,23 mld. KRW.

oodatud EyeGene kasum on −1,04 Bio. KRW.

EyeGene Inc specializes in the production and sale of diagnostic and therapy products for complex genetic eye diseases. The company provides innovative products and technologies to help doctors and patients make diagnoses and suggest treatments that have the potential to greatly improve vision. They focus on developing diagnostic tools to more accurately identify genetic causes of eye diseases, as well as therapy products that deliver medications specifically to the cells of the eye. They also offer consulting services for clinical trials and have research focuses in other areas such as macular degeneration. Overall, EyeGene Inc is a strong company in the field of complex genetic eye diseases and is expected to achieve many successes in the future.

EyeGene maksab dividendi 0 KRW, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu EyeGene jaoks arvutada või ettevõte ei maksa dividende välja.

EyeGene ISIN on KR7185490000.

EyeGene tähis on 185490.KQ.

Viimase 12 kuu jooksul maksis EyeGene dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab EyeGene tõenäoliselt dividendi summas 0 KRW.

EyeGene praegune dividenditootlus on .

EyeGene maksab kvartaalset dividendi. See makstakse välja kuudel .

EyeGene maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 KRW. See vastab dividenditootlusele 0 %.

EyeGene on liigitatud sektorisse 'Tervis'.

Viimase EyeGene dividendide saamiseks 13.9.2024 suuruses 0 KRW pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 13.9.2024.

Viimane dividendimakse toimus 13.9.2024.

Aastal 2023 maksis EyeGene 0 KRW dividende.

EyeGene dividendid makstakse välja KRW.